Open Access

ARTICLE

A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer

by Jiayi Huang¹, Xue Bai¹, Xiaofeng Xie¹, Liping Chen¹, Xiaofeng Lan¹, Qiuyi Zhang¹, Lin Song¹, Pengjiao Hong^2,3, Caiwen Du^1,*

1 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
2 Department of Gynecology and Obstetrics, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
3 College of Medical, Shenzhen University, Shenzhen, China

* Corresponding Author: Caiwen Du. Email:

Oncologie 2022, 24(1), 131-145. https://doi.org/10.32604/oncologie.2022.019881

Received 21 October 2021; Accepted 18 February 2022; Issue published 31 March 2022

Abstract

Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The efficacy, in terms of progression-free survival and overall survival, and safety of oral vinorelbine were evaluated. Results: At a median follow-up period of 17.0 months, 152 patients finally exhibited disease progression, and 55 succumbed to the disease. During the follow-up, 53 patients demonstrated a partial response, and 106 achieved a stable disease, with an objective response rate of 27.3%. Additionally, 118 patients demonstrated a partial response or stable disease for ≥24 weeks, with a clinical benefit rate of 60.8%. The median progression-free survival was 6.2 months (95% confidence interval, 5.0–7.4), and the median overall survival was not evaluated. No treatment-associated mortalities occurred. The most common adverse events included leukopenia (73.2%), neutropenia (72.7%), anemia (65.5%), and diarrhea (46.9%). Conclusions: Oral vinorelbine appears to be efficacious for metastatic breast cancer with acceptable toxicity for real-world use in China.

---

Keywords

---